Evidence map›Paper›PMID 41252108›Full record

ReviewMolecular biotechnology2026

Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer.

M Kevin, Srinidhi Varadharajan, P K Praveen Kumar, Shreeiya Swaminathan, R Dharshini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M KevinDepartment of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Sriperumbudur Tk, Tamilnadu, 602117, India.
Srinidhi VaradharajanDepartment of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Sriperumbudur Tk, Tamilnadu, 602117, India.
P K Praveen KumarDepartment of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Sriperumbudur Tk, Tamilnadu, 602117, India. praveenpk@svce.ac.in.
Shreeiya SwaminathanDepartment of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Sriperumbudur Tk, Tamilnadu, 602117, India.
R DharshiniDepartment of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Sriperumbudur Tk, Tamilnadu, 602117, India.

Funding

AICTE IR2022-773491ANRF SERB/TAR/2021/000250
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, representing around 97% of cases in humans. Mitochondria play a crucial role in slowing the progression of HCC and are utilized in developing precision medicine strategies targeting various mitochondria-related pathways. Recent developments in nanomedicine exploit the unique features of nanoparticles for improving drug delivery and efficacy specifically to mitochondria, bypassing the problems related to conventional chemotherapy. Mitochondria-targeted nanomedicines are developed for damaging mitochondrial DNA in liver cancer tissues by increasing reactive oxygen species perturbing redox balance and respiratory chain. This review emphasizes the future of mitochondrial-targeted nanomedicine in transforming liver cancer management and encourages an attempt to continuously improve these strategies to provide patients with better survival chances and quality of life.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsMitochondriaNanomedicineAnimalsDNA, MitochondrialDrug Delivery SystemsHumansNanoparticlesReactive Oxygen SpeciesAntineoplastic AgentsDNA, MitochondrialReactive Oxygen SpeciesHepatocellular carcinomaLiver cancerMitochondriaNanomedicine

Identifiers

PMID41252108

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.